Startseite Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population

  • Osman Oğuz ORCID logo EMAIL logo , Kerim Erhan Palaoğlu ORCID logo und Said Incir ORCID logo
Veröffentlicht/Copyright: 7. April 2025
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 63 Heft 9

Abstract

Objectives

This study aimed to investigate the prevalence of macroprolactinemia and the changes in hyperprolactinemia status over time among hyperprolactinemic patients in the Turkish population.

Methods

A retrospective study was conducted on 3,013 patient records from a central university hospital between October 2023 and October 2024. Of these, 634 hyperprolactinemic samples (Prolactin >15.2 μg/L in males, >23.3 μg/L in females) were analyzed using polyethylene glycol (PEG) precipitation method. Post-PEG prolactin levels were measured using electrochemiluminescence immunoassay, with the recovery percentage (R%) calculated as the ratio of prolactin post-PEG precipitation to total prolactin, where R% values below 40 % were indicative of macroprolactinemia. The change in R% values was analyzed in 63 hyperprolactinemic patients who underwent restesting.

Results

Macroprolactinemia prevalence was found as 5.67 % of hyperprolactinemic patients with no macroprolactinemia cases observed at PRL levels above 85.40 μg/L. Male patients had significantly higher R% values than females (p=0.003). In the gray zone (R%: 40–60), 29.03 % of patients were classified as truly hyperprolactinemic. Repeated tests after an average of four months showed stable R% values in most cases, with only two patients changing classification between macroprolactinemia and true hyperprolactinemia.

Conclusions

The prevalence of macroprolactinemia in hyperprolactinemic Turkish patients was relatively low. As prolactin values increase, true hyperprolactinemia is more commenly observed instead of macroprolactinemia. Short-term retesting for macroprolactinemia may not be necessary unless clinical conditions change significantly. Accurate diagnosis requires method-specific cutoffs and further prospective studies using gold-standard methods like gel filtration chromatography.

Keywords: big prolactin; hyperprolactinemia; immunoassay interference; macroprolactin polyethylene glycol (PEG)
Corresponding author: Osman Oğuz, Associate Professor, Clinical Laboratory, VKV American Hospital, Güzelbahçe Street, Istanbul, P.C: 34365, Türkiye, E-mail:

  1. Research ethics: 2025.076.IRB1.13 Osman OğuzTürk Toplumunda Makroprolaktinemi Yaygınlığı ve Tanısal Algoritması. Approved by Koç University Ethics Committee.

  2. Informed consent: Not applicable.

  3. Author contributions: Osman Oğuz: Concept + data collection and analyses + writing. Kerim Erhan Palaoğlu: Concept + design. Said İncir: Concept + data analyses + literature review. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Available. Access can be provided if desired.

References

1. Uğurlu, AK, Gündoğan, SÇ. Hiperprolaktinemisi olan pediatrik olguların klinik özelliklerinin ve hiperprolaktinemi etiyolojilerinin değerlendirilmesi. Dicle Med J 2024;51:128–34.10.5798/dicletip.1451742Suche in Google Scholar

2. Gibney, J, Smith, TP, McKenna, TJ. Clinical relevance of macroprolactin. Clin Endocrinol 2005;62:633–43. https://doi.org/10.1111/j.1365-2265.2005.02243.x.Suche in Google Scholar PubMed

3. Izuchukwu, ECO, Okpara, HC, Ilechukwu, OU. Macroprolactin and macroprolactinaemia: a narrative review. Magna Sci Adv Res 2023;8:187–94.10.30574/msarr.2023.8.1.0065Suche in Google Scholar

4. Lim, MH, Ho, CKM. Macroprolactin screening in 464 patients with hyperprolactinaemia. Malays J Pathol 2022;44:261–7.Suche in Google Scholar

5. Koniares, K, Benadiva, C, Engmann, L, Nulsen, J, Grow, D. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep 2023;4:245–50. https://doi.org/10.1016/j.xfre.2023.05.005.Suche in Google Scholar PubMed PubMed Central

6. Livingston, M, Hashmi, SF, Ramachandran, S, Laing, I, Heald, A. Macroprolactin over time: is there any point in rechecking it in people with a persistently elevated serum prolactin? Clin Endocrinol 2024;100:450–8. https://doi.org/10.1111/cen.15051.Suche in Google Scholar PubMed

7. Beltran, L, Fahie, WMN, McKenna, TJ, Kavanagh, L, Smith, TP. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673–81. https://doi.org/10.1373/clinchem.2008.105312.Suche in Google Scholar PubMed

8. Dirican, M, Acikgoz, HE, Sarandol, E. Evaluation of percentage recovery together with modified reference range in hyperprolactinemia. Turk J Biochem 2020;45:37–43.10.1515/tjb-2018-0377Suche in Google Scholar

9. Olukoga, AO, Kane, JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol 1999;51:119–26. https://doi.org/10.1046/j.1365-2265.1999.00757.x.Suche in Google Scholar PubMed

10. Westgard, QC. Quality requirements, desirable biological variation database specifications. Available from: https://westgard.com/clia-a-quality/quality-requirements/biodatabase1.html [Accessed 14 Feb 2025].Suche in Google Scholar

11. Melmed, S, Casanueva, FF, Hoffman, AR, Kleinberg, DL, Montori, VM, Schlechte, JA, et al.. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88. https://doi.org/10.1210/jc.2010-1692.Suche in Google Scholar PubMed

12. Soh, NAAC, Yaacob, NM, Omar, J, Mohammed Jelani, A, Shafii, N, Tuan, ITS, et al.. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Publ Health 2020;17:8199. https://doi.org/10.3390/ijerph17218199.Suche in Google Scholar PubMed PubMed Central

13. Rufo, E, Martinez, CS, Jimenez, AL, Fernandez, PC, Barallat, J, Granada, ML. Marked geographical variation in the prevalence of macroprolactinemia. Clin Chem Lab Med 2022;60:71–4. https://doi.org/10.1515/cclm-2021-1124.Suche in Google Scholar PubMed

14. Sherazi, NA, Baig, MZ, Khan, AH. Frequency of macroprolactin in hyperprolactinemia. J Coll Physicians Surg Pak 2018;28:93–7. https://doi.org/10.29271/jcpsp.2018.02.93.Suche in Google Scholar PubMed

15. Heald, AH, Blantern, E, Anderson, S, Radford, D, Qureshi, Z, Nair, S, et al.. Quantitative adjustment for macroprolactin is an integral part of laboratory assessment of hyperprolactinaemia. Exp Clin Endocrinol Diabetes 2012;120:376–80. https://doi.org/10.1055/s-0032-1304618.Suche in Google Scholar PubMed

16. Soh, NAAC, Omar, J, Mohamed, WMIW, Abdullah, MR, Yaacob, NM. Low prevalence of macroprolactinaemia among patients with hyperprolactinaemia screened using polyethylene glycol 8000. J Taibah Univ Med Sci 2016;11:464–8.10.1016/j.jtumed.2016.08.001Suche in Google Scholar

17. Samson, SL, Hamrahian, AH, Ezzat, S, American Association of Clinical Endocrinologists. American college of endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 2015;21:1427–35. https://doi.org/10.4158/ep15938.dsc.Suche in Google Scholar

18. McCudden, CR, Sharpless, JL, Grenache, DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411:155–60. https://doi.org/10.1016/j.cca.2009.10.020.Suche in Google Scholar PubMed PubMed Central

19. Casanueva, FF, Molitch, ME, Schlechte, JA, Abs, R, Bonert, V, Bronstein, MD, et al.. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265–73. https://doi.org/10.1111/j.1365-2265.2006.02562.x.Suche in Google Scholar PubMed

20. Beda, MK, Pisarek, H, Komorowski, J, Swietoslawski, J, Fuss, CJ, Winczyk, K. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. J Physiol Pharmacol 2014;65:359–64.Suche in Google Scholar

21. Aw, T, Lau, C. The importance of macroprolactin in the diagnosis of hyperprolactinemia. Endocrinol Diabetes Metab 2021;3:75–9. https://doi.org/10.54178/jsedmv3i3001.Suche in Google Scholar

22. Landberg, E, Dahlström, U, Alehagen, U. Serum prolactin and macroprolactin in heart failure: no relation to established laboratory or clinical parameters. Ann Clin Biochem 2011;48:51–6. https://doi.org/10.1258/acb.2010.010164.Suche in Google Scholar PubMed

23. Nguyen, KQN, Langevin, RH, McPhaul, MJ, Hashim, IA. Circulating macroprolactin exhibits molecular heterogeneity and is not exclusively an antibody complex. Clin Chim Acta 2021;514:90–5.10.1016/j.cca.2020.12.018Suche in Google Scholar PubMed

24. Barth, JH, Lippiatt, CM, Gibbons, SG, Desborough, R. Observational studies on macroprolactin in a routine clinical laboratory. Clin Chem Lab Med 2018;56:1259–62. https://doi.org/10.1515/cclm-2018-0074.Suche in Google Scholar PubMed

25. Jamaluddin, FA, Sthaneshwar, P, Hussein, Z, Othman, NA, Peng, CS. Importance of screening for macroprolactin in all hyperprolactinaemic sera. Malays J Pathol 2013;35:59.Suche in Google Scholar

26. Chen, YJ, Song, GZ, Wang, ZN. A new criteria for screening macroprolactinaemia using polyethylene glycol treatment combined with different assays for prolactin. Eur Rev Med Pharmacol Sci 2016;20:1788–94.Suche in Google Scholar

27. Fahie, WM, Smith, TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metabol 2013;27:725–42. https://doi.org/10.1016/j.beem.2013.07.002.Suche in Google Scholar PubMed

28. Hattori, N, Aisaka, K, Shimatsu, A. A possible cause of the variable detectability of macroprolactin by different immunoassay systems. Clin Chem Lab Med 2016;54:603–8. https://doi.org/10.1515/cclm-2015-0484.Suche in Google Scholar PubMed

29. Hu, Y, Ni, J, Zhang, B, Cheng, W, Zhang, H, Ye, H, et al.. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord 2021;21:1–7. https://doi.org/10.1186/s12902-021-00861-z.Suche in Google Scholar PubMed PubMed Central

30. Overgaard, M, Pedersen, SM. Serum prolactin revisited: parametric reference intervals and cross-platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin Chem Lab Med 2017;55:1744–53. https://doi.org/10.1515/cclm-2016-0902.Suche in Google Scholar PubMed

31. Coleman, K, Saleem, M. Reference intervals for serum prolactin concentrations: analytical and clinical considerations. Rev Endocr Metab Disord 2024;25:995–1002. https://doi.org/10.1007/s11154-024-09927-4.Suche in Google Scholar PubMed

32. Radavelli-Bagatini, S, Lhullier, FL, Mallmann, ES, Spritzer, PM. Macroprolactinemia in women with hyperprolactinemia: a 10-year follow-up. Neuroendocrinol Lett 2013;34:207–11.Suche in Google Scholar

33. Saparamadu, AADNS, Lam, CWL, Lim, LC, Lee, J. Prolactin assay interference by macroprolactin. Clin Lab 2021;67. https://doi.org/10.7754/clin.lab.2020.201108.Suche in Google Scholar PubMed

34. Richa, V, Rahul, G, Sarika, A. Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice. J Reproduction Infertil 2010;11:161–7.Suche in Google Scholar
Received: 2025-02-14
Accepted: 2025-03-26
Published Online: 2025-04-07
Published in Print: 2025-08-26

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Macroprolactinaemia – some progress but still an ongoing problem
  4. Review
  5. Understanding the circulating forms of cardiac troponin: insights for clinical practice
  6. Opinion Papers
  7. New insights in preanalytical quality
  8. IFCC recommendations for internal quality control practice: a missed opportunity
  9. Genetics and Molecular Diagnostics
  10. Evaluation of error detection and treatment recommendations in nucleic acid test reports using ChatGPT models
  11. General Clinical Chemistry and Laboratory Medicine
  12. Pre-analytical phase errors constitute the vast majority of errors in clinical laboratory testing
  13. Improving the efficiency of quality control in clinical laboratory with an integrated PBRTQC system based on patient risk
  14. IgA-type macroprolactin among 130 patients with macroprolactinemia
  15. Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
  16. Defining dried blood spot diameter: implications for measurement and specimen rejection rates
  17. Screening primary aldosteronism by plasma aldosterone-to-angiotensin II ratio
  18. Assessment of serum free light chain measurements in a large Chinese chronic kidney disease cohort: a multicenter real-world study
  19. Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection
  20. Direct screening and quantification of monoclonal immunoglobulins in serum using MALDI-TOF mass spectrometry without antibody enrichment
  21. Effect of long-term frozen storage on stability of kappa free light chain index
  22. Impact of renal function impairment on kappa free light chain index
  23. Standardization challenges in antipsychotic drug monitoring: insights from a national survey in Chinese TDM practices
  24. Potential coeliac disease in children: a single-center experience
  25. Vitamin D metabolome in preterm infants: insights into postnatal metabolism
  26. Candidate Reference Measurement Procedures and Materials
  27. Development of commutable candidate certified reference materials from protein solutions: concept and application to human insulin
  28. Reference Values and Biological Variations
  29. Biological variation of serum cholinesterase activity in healthy subjects
  30. Hematology and Coagulation
  31. Diagnostic performance of morphological analysis and red blood cell parameter-based algorithms in the routine laboratory screening of heterozygous haemoglobinopathies
  32. Cancer Diagnostics
  33. Promising protein biomarkers for early gastric cancer: clinical performance of combined detection
  34. Infectious Diseases
  35. The accuracy of presepsin in diagnosing neonatal late-onset sepsis in critically ill neonates: a prospective study
  36. Corrigendum
  37. The Unholy Grail of cancer screening: or is it just about the Benjamins?
  38. Letters to the Editor
  39. Analytical validation of hemolysis detection on GEM Premier 7000
  40. Reconciling reference ranges and clinical decision limits: the case of thyroid stimulating hormone
  41. Contradictory definitions give rise to demands for a right to unambiguous definitions
  42. Biomarkers to measure the need and the effectiveness of therapeutic supplementation: a critical issue
https://doi.org/10.1515/cclm-2025-0177
Schlagwörter für diesen Artikel
big prolactin; hyperprolactinemia; immunoassay interference; macroprolactin polyethylene glycol (PEG)

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Macroprolactinaemia – some progress but still an ongoing problem
  4. Review
  5. Understanding the circulating forms of cardiac troponin: insights for clinical practice
  6. Opinion Papers
  7. New insights in preanalytical quality
  8. IFCC recommendations for internal quality control practice: a missed opportunity
  9. Genetics and Molecular Diagnostics
  10. Evaluation of error detection and treatment recommendations in nucleic acid test reports using ChatGPT models
  11. General Clinical Chemistry and Laboratory Medicine
  12. Pre-analytical phase errors constitute the vast majority of errors in clinical laboratory testing
  13. Improving the efficiency of quality control in clinical laboratory with an integrated PBRTQC system based on patient risk
  14. IgA-type macroprolactin among 130 patients with macroprolactinemia
  15. Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
  16. Defining dried blood spot diameter: implications for measurement and specimen rejection rates
  17. Screening primary aldosteronism by plasma aldosterone-to-angiotensin II ratio
  18. Assessment of serum free light chain measurements in a large Chinese chronic kidney disease cohort: a multicenter real-world study
  19. Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection
  20. Direct screening and quantification of monoclonal immunoglobulins in serum using MALDI-TOF mass spectrometry without antibody enrichment
  21. Effect of long-term frozen storage on stability of kappa free light chain index
  22. Impact of renal function impairment on kappa free light chain index
  23. Standardization challenges in antipsychotic drug monitoring: insights from a national survey in Chinese TDM practices
  24. Potential coeliac disease in children: a single-center experience
  25. Vitamin D metabolome in preterm infants: insights into postnatal metabolism
  26. Candidate Reference Measurement Procedures and Materials
  27. Development of commutable candidate certified reference materials from protein solutions: concept and application to human insulin
  28. Reference Values and Biological Variations
  29. Biological variation of serum cholinesterase activity in healthy subjects
  30. Hematology and Coagulation
  31. Diagnostic performance of morphological analysis and red blood cell parameter-based algorithms in the routine laboratory screening of heterozygous haemoglobinopathies
  32. Cancer Diagnostics
  33. Promising protein biomarkers for early gastric cancer: clinical performance of combined detection
  34. Infectious Diseases
  35. The accuracy of presepsin in diagnosing neonatal late-onset sepsis in critically ill neonates: a prospective study
  36. Corrigendum
  37. The Unholy Grail of cancer screening: or is it just about the Benjamins?
  38. Letters to the Editor
  39. Analytical validation of hemolysis detection on GEM Premier 7000
  40. Reconciling reference ranges and clinical decision limits: the case of thyroid stimulating hormone
  41. Contradictory definitions give rise to demands for a right to unambiguous definitions
  42. Biomarkers to measure the need and the effectiveness of therapeutic supplementation: a critical issue
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 9.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0177/html
Button zum nach oben scrollen